TORONTO, June 25, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (TSX: CXR) (OTCQX: CHEHF), announced today that all of the nominees listed in the Company's Management Information Circular, dated May 25, 2015, for the 2015 Annual General Meeting of shareholders held on June 25, 2015, in Toronto, Ontario, (the "Meeting") were elected as members of Concordia's Board of Directors ("Board"). The five (5) candidates nominated for election were elected by a majority of the shareholders present in person or represented by proxy at the Meeting, as follows:
Mark L. Thompson
Concordia is also pleased to announce today that the newly elected Board has appointed Mark Thompson as the Chairman of the Board in addition to his role as Chief Executive Officer of Concordia. Mr. Thompson has stepped down from his role as President of Concordia and Mr. Wayne Kreppner has been promoted to the role of President, in addition to his role as Chief Operating Officer of Concordia.
The newly elected Board has also appointed Jordan Kupinsky as the Lead Independent Director of the Board. In addition, the newly elected Board has approved the appointment of Ms. Fuhrmann (Chair) and Messrs. Kupinsky and Borkowski to the Audit Committee of the Company, Messrs. Kupinsky (Chair) and Deeth and Ms. Fuhrmann to the Nominating and Corporate Governance Committee of the Company and Messrs. Deeth (Chair), Kupinsky and Borkowski to the Human Resources and Compensation Committee of the Company.
Concordia is also pleased to announce today that its shareholders have approved the appointment of PricewaterhouseCoopers LLP as the auditor of Concordia to hold office until the next annual meeting of shareholders.
Concordia is a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs. Concordia's legacy pharmaceutical division, Concordia Pharmaceuticals Inc., consists of a portfolio of branded products and authorized generic contracts, including branded products such as Nilandron®, for the treatment of metastatic prostate cancer; Dibenzyline®, for the treatment of pheochromocytoma; Lanoxin®, for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil®, for the treatment of lupus and rheumatoid arthritis, Donnatal® for the treatment of irritable bowel syndrome and Zonegran® (zonisamide) for treatment of partial seizures in adults with epilepsy. Concordia's orphan drugs division, Concordia Laboratories Inc., manufactures Photofrin®. Photofrin® is marketed by Pinnacle Biologics, Inc. in the United States.
Concordia operates out of facilities in Oakville, Ontario; Bridgetown, Barbados; and Roanoke, Virginia and also has a specialty healthcare distribution division that operates out of Kansas City, Missouri. Pinnacle Biologics, Inc. is located in Chicago, Illinois.
SOURCE Concordia Healthcare Corp.